Navigation Links
Sunesis in Medical Technology

SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases

SOUTH SAN FRANCISCO, Calif., Sept. 5 /PRNewswire-FirstCall/ -- SARcode Corporation, a private company focused on small molecule LFA-1 inhibitors to treat inflammatory diseases, and Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced SARcode's initiation of a Phase 1 clinical trial of ...

Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology

... SAN FRANCISCO , Dec. 7 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today anno...erated. Conference Call Information sunesis management will host a conference call on Tuesday,...ors and Media - Calendar of Events" section of the sunesis website at www.sunesis.com . The webcast will be...

Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH

...NCISCO, Calif., Dec. 1 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biophar...60 Conference Call Information sunesis management will host a conference call to discuss ...ors and Media - Calendar of Events" section of the sunesis website at www.sunesis.com . The webcast will be...

Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium

...SH," said Daniel Swisher, Chief Executive Officer, sunesis Pharmaceuticals. "Our goal is to advance voreloxin...been escalated to 75 mg/m2 dosed every four weeks. sunesis expects to complete enrollment of the 75 mg/m2 coh...ar survival rates at less than 30 percent. About sunesis Pharmaceuticals ...

Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association

...n an acute need for new treatment options. About sunesis Pharmaceuticals sunesis is a clinical-stage biopharmaceutical company focu...or the treatment of solid and hematologic cancers. sunesis has built a highly experienced cancer drug develop...

Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)

... In conjunction with this strategic restructuring, sunesis expanded the company's late-stage development lead...tently well tolerated in multiple clinical trials. sunesis is currently conducting Phase 2 clinical trials of...nation with cytarabine for the treatment of AML. sunesis continues ongoing trials in its earlier-stage clin...

Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting

...ofile demonstrated in this Phase 2 clinical trial, sunesis increased the dose of voreloxin in this trial to 6...een observed. Based on voreloxin's safety profile, sunesis recently announced that the protocol for the ongoi...25 percent to 75 mg/m(2) given once every 28 days. sunesis expects to enroll approximately 30 patients at thi...

Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress

...will be available following each conference on the sunesis corporate website at http://www.sunesis.com . About Sunesis' Oncology Programs sunesis has built a rich portfolio of product candidates i...al in patients with advanced solid tumors. About sunesis Pharmaceuticals ...

Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia

...a from this trial indicate clear clinical benefit, sunesis could initiate a pivotal trial in this highly unde...medical conference toward the end of this year." sunesis previously reported promising results from its Pha...lerated weekly dose of 72 mg/m2 was established. sunesis also announced today that voreloxin has been accep...

Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research

...by the MMRC Validation Team, in collaboration with sunesis scientists, of SNS-032 in human myeloma cell lines...cell lymphoma cell lines" (Abstract #756). About sunesis Pharmaceuticals sunesis is a clinical-stage biopharmaceutical company focu...

Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research

...ch (AACR) being held April 12-16 in San Diego, CA. sunesis has built a portfolio of product candidates in onc...ibit Hall B-F, San Diego Convention Center About sunesis Pharmaceuticals sunesis is a clinical-stage biopharmaceutical company focu...

Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer

...ar survival rates at less than 30 percent. About sunesis Pharmaceuticals sunesis is a clinical-stage biopharmaceutical company focu...rapeutics for oncology and other serious diseases. sunesis has built a broad product candidate portfolio thro...

Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology

... Center in Atlanta, Georgia. On December 10, 2007, sunesis management will host a conference call for investo... a.m. to 7:00 p.m. Conference Call Information sunesis management will host a conference call to discuss ...ors and Media - Calendar of Events" section of the sunesis website at http://www.sunesis.com . Please log on...

Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference

...- /ADVANCE FOR RELEASE AT 3:30 P.M. EDT, TODAY/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a clinical...nt progressed within 60 days of initial response. sunesis plans to enroll approximately 55 patients in this ...hirty-one patients have been enrolled to date, and sunesis expects to complete enrollment and present additio...

Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314

...ug-resistant models. About SNS-314 Discovered by sunesis using the company's discovery platform, SNS-314 is...le in the abnormal proliferation of tumors. About sunesis Pharmaceuticals sunesis is a clinical-stage biopharmaceutical company focu...

Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility

..., Calif., March 20, 2007 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. , presented non-clinical dat...er Therapies (TAT 2007) meeting held in Amsterdam, sunesis researchers presented results showing SNS-314's an...of this year. About Sunesis' Oncology Programs sunesis has built a rich portfolio of product candidates i...

Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research

..., Calif., April 13, 2007 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. today announced that the com... 7, board #1. About Sunesis' Oncology Programs sunesis has built a rich portfolio of product candidates i...hibition of the cell-cycle and survival signaling. sunesis is currently conducting Phase 2 clinical trials in...

Sunesis Presents Data Supporting SNS-032's Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting

...l lymphoma. Non-clinical studies were conducted by sunesis evaluating SNS-032's mechanism of action and in vi...ce apoptosis. About Sunesis' Oncology Programs sunesis has built a rich portfolio of product candidates i...hibition of the cell cycle and survival signaling. sunesis is currently conducting Phase 2 clinical trials in...

Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association

...O, Calif., June 01, 2007 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. today announced that the com...session. About Sunesis' Oncology Programs sunesis has built a rich portfolio of product candidates i...hibition of the cell-cycle and survival signaling. sunesis is currently conducting Phase 2 clinical trials in...

Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association

...O, Calif., June 11, 2007 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. presented positive data from...odels while sparing normal hematopoietic recovery. sunesis plans to initiate a Phase 1b clinical trial of SNS...NS-032 to Flavopirodol In a second presentation, sunesis reported the results of studies evaluating its cyc...

Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference

...O, Calif., July 03, 2007 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. today announced that Eric Bj...ss the webcast of the presentation by visiting the sunesis website at sunesis website for two weeks until July 26, 2007. Optio...
Other Tags
(Date:9/19/2014)... professor will study multifunctional and specialized spinal cord ... National Science Foundation grant in the amount of ... professor in the Department of Biology, OU College ... differences between the multifunctional and specialized spinal cord ... and what connections they make. Berkowitz will ...
(Date:9/18/2014)... - Washington State University researchers have developed a unique ... power waste cleanup in rural areas. , The ... an inexpensive and quick way to clean up waste ... while reducing pollution. , Professor Haluk Beyenal and ... Engineering and Architecture discuss the system in the online ...
(Date:9/18/2014)... A novel robotic system that can operate inside the ... as part of a biomedical research partnership program at ... of determining if the robot, in conjunction with real-time ... accurate, less costly, and less discomforting for the patient. ... prostate cancer therapies with greater precision. , Developed by ...
Breaking Biology News(10 mins):Researchers develop unique waste cleanup for rural areas 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5
(Date:9/20/2014)... Increases in household, construction and ... treatment volumes. However, government regulations and higher landfill ... According to IBISWorld industry analyst Alen Allday, “over ... at reducing the volume of waste generated, and ... Still, a large proportion of waste generated by ...
(Date:9/20/2014)... York (PRWEB) September 20, 2014 ... to grow in federal court, Bernstein Liebhard LLP ... Drug Administration (FDA) have voted overwhelmingly to recommend ... in men be subjected to further study in ... a report published on September 18th by Bloomberg.com, ...
(Date:9/20/2014)... Sept. 20, 2014 (HealthDay News) -- As flu season ... infection is to get a flu shot and a ... A primary care doctor can vaccinate people against the ... patients may have. Retail stores may provide flu shots ... advice, said Dr. Jorge Parada, medical director of infection ...
(Date:9/20/2014)... New York (PRWEB) September 20, 2014 ... morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in gynecological surgeries ... yet another insurer has announced plans to end ... posted on its website last month, Harrisburg, Pennsylvania-based ... effective November 1, 2014. The insurer said its ...
(Date:9/20/2014)... Traditionally dentists have advised their patients against drinking coffee and ... re-visiting that advice and changing his stance after considering two ... on oral health. “There’s good news and great news,” says ... in protecting against gum disease, and red wine can help ... from the September 2014 issue of Boston University School ...
Breaking Medicine News(10 mins):Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:As Testosterone Lawsuits Grow, Bernstein Liebhard LLP Notes Overwhelming Vote Calling for Further Study of Testosterone Heart Risks 2Health News:As Testosterone Lawsuits Grow, Bernstein Liebhard LLP Notes Overwhelming Vote Calling for Further Study of Testosterone Heart Risks 3Health News:Get a Flu Shot During Checkup, Doctor Says 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 3Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 2Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 3
Other Contents